GERON CORP Shareholders' Equity
GERON CORP (GERN) had Shareholders' Equity of $218.61 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-05
- 2026-06-30: Stockholders' Equity Attributable to Parent $218.61M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $229.11M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $225.87M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $248.71M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $218.61M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $229.11M 10-Q · filed 2026-08-05 |
| 2025-12-31 | $225.87M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $248.71M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $259.53M 10-Q · filed 2026-08-05 |
| 2025-03-31 | $268.24M 10-Q · filed 2026-08-05 |
| 2024-12-31 | $280.32M 10-Q · filed 2026-08-05 |
| 2024-09-30 | $292.28M 10-Q · filed 2025-11-07 |
| 2024-06-30 | $306.69M 10-Q · filed 2025-11-07 |
| 2024-03-31 | $344.87M 10-Q · filed 2025-11-07 |
| 2023-12-31 | $247.95M 10-K · filed 2026-03-02 |
| 2023-09-30 | $290.61M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $298.43M 10-Q · filed 2024-11-07 |
| 2023-03-31 | $326.06M 10-Q · filed 2024-11-07 |
| 2022-12-31 | $80.00M 10-K · filed 2026-03-02 |
| 2022-09-30 | $108.17M 10-Q · filed 2023-11-02 |
| 2022-06-30 | $142.05M 10-Q · filed 2023-11-02 |
| 2022-03-31 | $97.49M 10-Q · filed 2023-11-02 |
| 2021-12-31 | $126.42M 10-K · filed 2025-02-27 |
| 2021-09-30 | $151.55M 10-Q · filed 2022-11-07 |
| 2021-06-30 | $176.21M 10-Q · filed 2022-11-07 |
| 2021-03-31 | $201.16M 10-Q · filed 2022-11-07 |
| 2020-12-31 | $210.95M 10-K · filed 2024-02-28 |
| 2020-09-30 | $232.83M 10-Q · filed 2021-11-09 |
| 2020-06-30 | $250.68M 10-Q · filed 2021-11-09 |
| 2020-03-31 | $120.81M 10-Q · filed 2021-11-09 |
| 2019-12-31 | $135.16M 10-K · filed 2023-03-16 |
| 2019-09-30 | $152.39M 10-Q · filed 2020-11-05 |
| 2019-06-30 | $157.04M 10-Q · filed 2020-11-05 |
| 2019-03-31 | $169.41M 10-Q · filed 2020-11-05 |
| 2018-12-31 | $177.73M 10-K · filed 2022-03-10 |
| 2018-09-30 | $183.47M 10-Q · filed 2019-11-06 |
| 2018-06-30 | $178.36M 10-Q · filed 2019-11-06 |
| 2018-03-31 | $101.13M 10-Q · filed 2019-11-06 |
| 2017-12-31 | $103.80M 10-K · filed 2021-03-11 |
| 2017-09-30 | $108.27M 10-Q · filed 2017-11-01 |
| 2017-06-30 | $113.01M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $117.25M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $122.38M 10-K · filed 2020-03-12 |
| 2016-09-30 | $128.91M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $130.31M 10-Q · filed 2016-08-03 |
| 2016-03-31 | $136.49M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $142.13M 10-K · filed 2019-03-07 |
| 2015-09-30 | $147.89M 10-Q · filed 2015-11-05 |
| 2015-06-30 | $118.36M 10-Q · filed 2015-08-05 |
| 2015-03-31 | $125.17M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $130.71M 10-K · filed 2018-03-16 |
| 2014-09-30 | $137.18M 10-Q · filed 2014-11-05 |
| 2014-06-30 | $144.58M 10-Q · filed 2014-08-11 |
| 2014-03-31 | $150.89M 10-Q · filed 2014-05-01 |
| 2013-12-31 | $59.76M 10-K · filed 2017-03-01 |
| 2013-09-30 | $61.88M 10-Q · filed 2013-11-07 |
| 2013-06-30 | $68.41M 10-Q · filed 2013-08-08 |
| 2013-03-31 | $76.06M 10-Q · filed 2013-05-03 |
| 2012-12-31 | $85.65M 10-K · filed 2016-03-10 |
| 2012-09-30 | $99.77M 10-Q · filed 2012-11-02 |
| 2012-06-30 | $114.20M 10-Q · filed 2012-08-03 |
| 2012-03-31 | $130.91M 10-Q · filed 2012-05-07 |
| 2011-12-31 | $146.60M 10-K · filed 2015-03-11 |
| 2011-09-30 | $175.21M 10-Q · filed 2011-11-03 |
| 2011-06-30 | $191.06M 10-Q · filed 2011-08-05 |
| 2010-12-31 | $192.74M 10-K · filed 2014-03-17 |
| 2009-12-31 | $172.58M 10-K · filed 2013-03-15 |
| 2008-12-31 | $168.46M 10-K · filed 2012-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |